Reshape Biotech vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Copenhagen YC W21 lab automation robots for biotech at $28.2M total ($20M Astanor Series A Apr 2024) and $8.3M revenue 2024; 500K+ hours saved annually serving alternative protein and sustainable ag competing with Opentrons for microbiology automation.
About
Reshape Biotech is a Copenhagen, Denmark-based laboratory automation robotics company — backed by Y Combinator (W21) with $28.2 million in total funding including a $20 million Series A led by Astanor Ventures in April 2024 with participation from YC — providing biotechnology companies, life sciences research organizations, and food technology companies with specialized single-function robots that automate repetitive microbiological laboratory workflows, generating $8.3 million in annual revenue in 2024 with a 55-person team. Reshape's robots have saved customers over 500,000 hours of manual lab work annually, serving the sustainable food technology and alternative protein sector (fermentation-based food production, precision fermentation, cultivated meat) alongside traditional biotech research laboratories that use microbiology workflows at scale.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.